DGX logo

Quest Diagnostics

DGX · What the business does, what can go wrong, and how options sellers approach it

What it does

Quest Diagnostics is an independent provider of diagnostic testing in the United States. Doctors, hospitals and employers send patient samples, such as blood or tissue, to Quest's laboratories. The lab runs the tests and returns results that help clinicians screen for, diagnose and monitor health conditions.

Its work spans routine blood tests, specialized (esoteric) testing, anatomic pathology, and drug and substance testing. A smaller side of the business offers testing for clinical trials, risk-assessment services and information technology tools.

How it makes money

Quest earns most of its revenue from fees for the tests it performs. Payers include commercial health insurers, government programs such as Medicare and Medicaid, hospitals that outsource lab work, employers and patients paying directly.

Revenue depends on test volume and on the price paid per test. Large laboratory networks can spread fixed costs, such as equipment, logistics and billing systems, across many samples.

Why investors own it

  • Testing demand tends to be steady, since much of it is tied to routine and ongoing healthcare.
  • Scale in a national network can support efficiency and relationships with insurers and health systems.
  • Long-term trends such as an aging population and growth in preventive care and advanced diagnostics may support volume.
  • It has historically returned cash through dividends and buybacks, which the company can change.

What can go wrong

  • Reimbursement pressure from insurers or government programs can lower prices.
  • Changes in healthcare policy or lab payment rules can affect revenue.
  • Competition from other national labs, hospital systems and regional players can limit pricing and volume.
  • Labor costs, supply costs and operational errors can weigh on profit.
  • Data breaches or billing problems can bring legal costs and hurt reputation.

What to watch

  • Test volumes (often called requisition volume)
  • Revenue per requisition
  • Operating margin
  • Growth in advanced and specialty testing
  • Changes in reimbursement and lab payment policy
  • Health system partnerships and outreach
  • Free cash flow and capital allocation

Options income angle

Options on DGX trade across several expirations but are typically less active than those on mega-cap stocks, so check bid-ask spreads before trading.

Implied volatility tends to rise ahead of quarterly earnings and around news on reimbursement policy or healthcare regulation. It often eases after the event.

One caution: an earnings report or policy surprise can move the stock sharply. A premium seller, through covered calls or cash-secured puts, can face a large loss on the stock or give up gains if shares jump.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 23, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Quest Diagnostics grew net revenues 10.0% to $3,097 million in the third quarter, and operating income rose 24.2% to $479 million. Most of the growth came from testing volume, helped by new relationships with Corewell Health and Fresenius Medical Care. Those relationships lowered revenue per test because they skew toward routine tests. The report also lists the impact of an incident described in an 8-K filed October 22, 2026 among its risks.

How the business did

  • Quarter: Net income attributable to Quest was $312 million versus $245 million a year earlier. Diluted earnings per share were $2.78 versus $2.16. Net revenues for the nine months were $9,035 million, up 9.8%, and diluted earnings per share were $7.86 versus $6.57.
  • Volume and price: Requisition volume (the count of test orders) rose 14.5%, and 9.5% of that came from the Corewell Health and Fresenius testing. Excluding those two, volume rose 5%. Revenue per requisition fell 4.2%, but excluding their mix effect it rose 1.7%, mainly from more tests per requisition.
  • Costs and one-time items: Cost of services rose $188 million on higher compensation and supplies. Selling, general and administrative expense rose $22 million. Items such as amortization, restructuring and acquisition-related charges reduced quarterly earnings per share by $0.22, versus $0.44 in the prior-year quarter, which included a $15 million legal charge. The nine-month tax rate of 22.5% was helped by about $11 million of tax benefits from resolving tax contingencies in the second quarter.
  • Cash and capital return: Operating cash flow for the nine months was $1,486 million versus $1,421 million. The company repurchased approximately $250 million of stock (1.2 million shares) and declared a quarterly dividend of $0.86 per share in each of the first three quarters, up from $0.80. Cash was $797 million, and $1.2 billion remained under the buyback authorization.
  • Debt: In May the company issued $500 million of 5.00% senior notes due June 2036 and used the proceeds, plus cash, to repay $500 million of 3.45% notes at maturity.

What management is watching

  • Costs: The Invigorate program aims for 3% annual cost savings and productivity gains to partly offset labor, benefit and reimbursement pressures. The company booked $14 million of pre-tax restructuring and integration charges in the nine months and says more may follow.
  • Spending: Capital expenditures are expected to be approximately $550 million for 2026, mostly lab equipment, automation and information technology. Management also points to Project Nova, a multi-year overhaul of its billing ("Order-to-Cash") processes.
  • Corewell venture: The Michigan venture, 51% owned by Quest and consolidated into its results, serves customers from existing facilities until a new laboratory opens during 2027.
  • Measures cited: Management points investors to requisition volume and revenue per requisition. Days sales outstanding, a gauge of how fast bills are collected, was 51 days versus 48 days at December 31, 2025, which the filing attributes to a shift in payer mix.

Follow DGX in Kortex

The Kortex app shows DGX's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.